サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1520532

抗線溶薬市場レポート：適応症、剤形、エンドユーザー、地域別、2024年～2032年

Antifibrinolytic Drugs Market Report by Indication, Form, End User, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 138 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.03円
抗線溶薬市場レポート：適応症、剤形、エンドユーザー、地域別、2024年～2032年
出版日: 2024年07月01日
発行: IMARC
ページ情報: 英文 138 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の抗線溶薬市場規模は2023年に169億米ドルに達しました。今後、IMARC Groupは、2024年から2032年にかけて3.97%の成長率（CAGR）を示し、2032年までに242億米ドルに達すると予測しています。

抗線溶薬とは、動脈や静脈における線溶や閉塞を防ぐために、血栓の形成を促進するために使用される医薬品を指します。これらの薬剤はプラスミノーゲンの活性化を阻害することにより、フィブリンの溶解を防ぎ、血栓の安定性を維持します。出血や血管腫瘍の治療、月経時の大量出血の緩和などに使用されます。また、侵襲的な手術中や手術後の出血の抑制にも使用されます。一般的に使用されている抗線溶薬には、トラネキサム酸、アプロチニン、アミノカプロン酸、セリンプロテアーゼ阻害薬などがあります。これらは口腔咽頭、鼻、消化管（GI）、子宮膣の粘膜出血の管理に広く使用されています。そのため、病院、診療所、外傷センター、外来手術センターなどで広く使用されています。

抗線溶薬市場動向：

交通事故、外傷、さまざまな出血性疾患の発生率が上昇していることは、市場の成長を促進する主な要因の1つです。さらに、月経痛に悩む女性や心臓血管および脳神経外科手術中の出血を予防するために抗線溶薬が広く採用されていることも、市場の成長を後押ししています。抗線溶薬は血栓溶解を防ぎ、出血を最小限に抑えるために不可欠です。これに伴い、遺伝性血管性浮腫や血友病に対する利用可能な治療法に関する大衆の健康意識と認識が高まっていることも、市場の成長に寄与しています。様々な技術の進歩や、整形外科患者の輸血を減らすために抗線溶療法の利用が増加していることも、他の成長促進要因として作用しています。製薬メーカーも、有効性と生体吸収性を高めた革新的な経口薬や静脈注射薬の開発を進めています。老年人口の増加やヘルスケアインフラの大幅な改善など、その他の要因も市場の成長を後押しすると予想されます。

本レポートで扱う主な質問

  • 世界の抗線溶薬市場の市場規模は？
  • 2024-2032年における世界の抗線溶薬市場の予想成長率は？
  • 世界の抗線溶薬市場を牽引する主な要因は？
  • 世界の抗線溶薬市場に与えたCOVID-19の影響は？
  • 世界の抗線溶薬市場における主要地域は？
  • 世界の抗線溶薬市場における主要プレーヤー／企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の抗線溶薬市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：適応症別

  • 婦人科
    • 市場動向
    • 市場予測
  • 遺伝性血管性浮腫
    • 市場動向
    • 市場予測
  • 線溶反応検査
    • 市場動向
    • 市場予測
  • 手術
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：形態別

  • 経口
    • 市場動向
    • 市場予測
  • 注射
    • 市場動向
    • 市場予測

第8章 市場内訳：エンドユーザー別

  • 病院と診療所
    • 市場動向
    • 市場予測
  • 外来手術センター
    • 市場動向
    • 市場予測
  • 外傷センター
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • ACIC Pharmaceuticals Inc.
    • Akorn Inc.
    • Aurobindo Pharma Limited
    • Ferring Pharmaceuticals
    • Novartis AG
    • Pfizer Inc.
    • Takeda Pharmaceutical Company Limited
    • Viatris Inc.
    • Vitruvias Therapeutics Inc.
図表

List of Figures

  • Figure 1: Global: Antifibrinolytic Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Antifibrinolytic Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Antifibrinolytic Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Antifibrinolytic Drugs Market: Breakup by Indication (in %), 2023
  • Figure 5: Global: Antifibrinolytic Drugs Market: Breakup by Form (in %), 2023
  • Figure 6: Global: Antifibrinolytic Drugs Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Antifibrinolytic Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Antifibrinolytic Drugs (Gynecology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Antifibrinolytic Drugs (Gynecology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Antifibrinolytic Drugs (Hereditary Angioedema) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Antifibrinolytic Drugs (Hereditary Angioedema) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Antifibrinolytic Drugs (Fibrinolytic Response Testing) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Antifibrinolytic Drugs (Fibrinolytic Response Testing) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Antifibrinolytic Drugs (Surgeries) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Antifibrinolytic Drugs (Surgeries) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Antifibrinolytic Drugs (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Antifibrinolytic Drugs (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Antifibrinolytic Drugs (Oral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Antifibrinolytic Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Antifibrinolytic Drugs (Injectable) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Antifibrinolytic Drugs (Injectable) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Antifibrinolytic Drugs (Hospitals and Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Antifibrinolytic Drugs (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Antifibrinolytic Drugs (Ambulatory Surgical Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Antifibrinolytic Drugs (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Antifibrinolytic Drugs (Trauma Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Antifibrinolytic Drugs (Trauma Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Antifibrinolytic Drugs (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Antifibrinolytic Drugs (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: North America: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: North America: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: United States: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: United States: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Canada: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Canada: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Asia-Pacific: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Asia-Pacific: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: China: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: China: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Japan: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Japan: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: India: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: India: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: South Korea: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: South Korea: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Australia: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Australia: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Indonesia: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Indonesia: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Others: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Others: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Europe: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Europe: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Germany: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Germany: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: France: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: France: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: United Kingdom: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: United Kingdom: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Italy: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Italy: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Spain: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Spain: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Russia: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Russia: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Others: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Others: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Latin America: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Latin America: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Brazil: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Brazil: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Mexico: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Mexico: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Others: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Others: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Middle East and Africa: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Middle East and Africa: Antifibrinolytic Drugs Market: Breakup by Country (in %), 2023
  • Figure 78: Middle East and Africa: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Global: Antifibrinolytic Drugs Industry: SWOT Analysis
  • Figure 80: Global: Antifibrinolytic Drugs Industry: Value Chain Analysis
  • Figure 81: Global: Antifibrinolytic Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Antifibrinolytic Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Antifibrinolytic Drugs Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 3: Global: Antifibrinolytic Drugs Market Forecast: Breakup by Form (in Million US$), 2024-2032
  • Table 4: Global: Antifibrinolytic Drugs Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Antifibrinolytic Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Antifibrinolytic Drugs Market: Competitive Structure
  • Table 7: Global: Antifibrinolytic Drugs Market: Key Players
目次
Product Code: SR112024A5672

The global antifibrinolytic drugs market size reached US$ 16.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 24.2 Billion by 2032, exhibiting a growth rate (CAGR) of 3.97% during 2024-2032.

Antifibrinolytic drugs refer to the pharmaceutical medicines used for promoting the formation of blood clots to prevent fibrinolysis or blockage in arteries and veins. These drugs inhibit the activation of plasminogen, thereby preventing the lysis of fibrin and maintaining clot stability. They are used for the treatment of hemorrhages, vascular tumors and providing relief from heavy menstrual bleeding. They are also used for controlling bleeding during or after invasive surgeries. Some commonly available antifibrinolytic drugs include tranexamic acid, aprotinin, aminocaproic acid and serine protease inhibitors. They are widely used for the management of mucosal bleeding in the oropharynx, nose, gastrointestinal (GI) tract and uterine-vaginal linings. As a result, they are extensively used across hospitals, clinics and trauma and ambulatory surgical centers.

Antifibrinolytic Drugs Market Trends:

The rising incidence of road accidents, traumas and various bleeding disorders is one of the key factors driving the growth of the market. Moreover, the widespread adoption of antifibrinolytic drugs to prevent blood loss in women suffering from menorrhagia and during cardiovascular and neurosurgeries is providing a thrust to the market growth. Antifibrinolytic drugs are essential for preventing clot lysis and minimizing blood loss. In line with this, increasing health consciousness and awareness among the masses regarding the available treatment alternatives for hereditary angioedema and hemophilia are also contributing to the growth of the market. Various technological advancements and the increasing utilization of antifibrinolytic therapy to reduce transfusion in orthopedic patients are acting as other growth-inducing factors. Pharmaceutical manufacturers are also developing innovative oral and intravenous drug variants with enhanced efficacy and bio-absorbability. Other factors, including the rising geriatric population and significant improvements in the healthcare infrastructure, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global antifibrinolytic drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on indication, form and end user.

Breakup by Indication:

Gynecology

Hereditary Angioedema

Fibrinolytic Response Testing

Surgeries

Others

Breakup by Form:

Oral

Injectable

Breakup by End User:

Hospitals and Clinics

Ambulatory Surgical Centers

Trauma Centers

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being ACIC Pharmaceuticals Inc., Akorn Inc., Aurobindo Pharma Limited, Ferring Pharmaceuticals, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Viatris Inc. and Vitruvias Therapeutics Inc.

Key Questions Answered in This Report

  • 1. How big is the global antifibrinolytic drugs market?
  • 2. What is the expected growth rate of the global antifibrinolytic drugs market during 2024-2032?
  • 3. What are the key factors driving the global antifibrinolytic drugs market?
  • 4. What has been the impact of COVID-19 on the global antifibrinolytic drugs market?
  • 5. What is the breakup of the global antifibrinolytic drugs market based on the indication?
  • 6. What are the key regions in the global antifibrinolytic drugs market?
  • 7. Who are the key players/companies in the global antifibrinolytic drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Antifibrinolytic Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Indication

  • 6.1 Gynecology
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Hereditary Angioedema
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Fibrinolytic Response Testing
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Surgeries
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Form

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Injectable
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals and Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ambulatory Surgical Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Trauma Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 ACIC Pharmaceuticals Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Akorn Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Aurobindo Pharma Limited
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
    • 14.3.4 Ferring Pharmaceuticals
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Novartis AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Pfizer Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Takeda Pharmaceutical Company Limited
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Viatris Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
    • 14.3.9 Vitruvias Therapeutics Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio